Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Fidia Spa ( (IT:FDA) ).
Fidia S.p.A. has revised its 2026 corporate events calendar, postponing the board meeting to approve the 2025 separate and consolidated financial statements from 16 April to 15 May 2026. The shareholders’ meeting to approve the 2025 accounts is now scheduled for 30 June 2026, while the board meeting to approve the half-year report as at 30 June 2026 is set for 29 September 2026.
The rescheduling stems from the need to give newly appointed CFO Roberto Iammarino sufficient time to complete review and verification activities on financial documentation requiring his certification. The company will also use the extended 180-day term allowed under Italian law for shareholder approval of the 2025 financial statements due to consolidated reporting obligations and has committed to promptly informing the market of any further changes to the calendar.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.11 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
More about Fidia Spa
Fidia S.p.A., based in Turin and listed on Euronext Milan, is a global leader in numerical control technology and high-performance integrated milling systems. Its solutions, including numerical controls, high-speed milling machines and CAM software, are used mainly in the automotive mould sector and in aerospace, with the group employing around 133 people and covering the entire milling process from programming to finished part.
Average Trading Volume: 1,889,931
Technical Sentiment Signal: Strong Sell
Current Market Cap: €436.2K
See more data about FDA stock on TipRanks’ Stock Analysis page.